Pancreatic adenocarcinoma |
In vitro and in vivo xenografts |
Gemcitabine |
Thymidylate synthetase inhibition |
Increased lipogenesis |
Increased FASN expression |
[43] |
Ovarian cancer |
In vitro cell lines and primary cells |
Cisplatin |
DNA binding |
Increased lipogenesis |
Increased FASN expression |
[44] |
Breast cancer |
In vitro |
Increased lipogenesis |
Increased FASN expression |
[45] |
Bladder cancer |
In vitro |
Increased lipogenesis |
Increased cytosolic ACSS2 expression |
[46] |
Ovarian cancer |
In vitro and in vivo xenografts |
Carboplatin |
DNA binding |
Increased lipolysis |
Adipocyte-Induced FABP4 Expression |
[47] |
Breast cancer |
In vitro cell lines and patient tissue and in vivo |
Paclitaxel |
Antimicrotubule agent |
Increased lipolysis |
High mRNA levels of CPT1B and FAO |
[48] |
Breast cancer |
In vitro |
Radiation therapy |
DNA double strand breaks |
Increased lipolysis |
High CPT1A andCPT2 expression and increased FAO |
[49] |
Nasopharyngeal carcinoma |
In vitro cell lines and tissue assay |
Increased lipolysis |
High CPT1A expression and increased FAO |
[50] |
Head and Neck Squamous Cell Cancer |
In vitro |
Increased lipogenesis and decreased lipolysis |
Increased FASN expression |
[51] |
AML |
In vitro primary cells and in vivo patient derived xenografts |
Cytarabine |
Nucleoside analogue of cytosine |
Increased lipolysis |
Increased CD36 expression |
[52] |
Acute myeloid leukemia |
In vitro |
Mitoxantrone |
Type II topoisomerase inhibitor |
Increased lipogenesis and lipolysis |
Increased lipid droplets and increased OXPHOS |
[53] |
Breast cancer |
In vitro |
Doxorubicin and mitoxantrone |
DNA binding and type II topoisomerase inhibitor |
Increased lipogenesis |
Increased FASN expression |
[54] |
Burkitt lymphoma |
In vitro |
Bortezomib |
Inhibition of the 26S proteasome |
Increased lipogenesis |
Induction of a GGPP-dependent survival pathway |
[55] |
Melanoma |
In vitro and in vivo xenografts |
BRAFi and MEKi |
Selective inhibitors of mutated BRAF/MEK |
Increased lipolysis |
Increased peroxisomal β-oxidation |
[30] |
Non-small cell lung cancer |
In vitro and in vivo xenografts |
Gefitinib |
Inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase |
Increased lipogenesis |
Increased membrane fluidity by high lipid droplet content and SCD1 expression |
[41] |
In vitro and in vivo xenografts |
Increased lipogenesis |
High cholesterol level in lipid rafts |
[56] |
Breast cancer |
In vitro |
Increased lipogenesis |
EGFR sequestrated within plasma membrane cholesterol lipid rafts |
[57] |
Breast cancer |
In vitro and in vivo xenografts |
Lapatinib |
Inhibitor of EGFR/HER1 and HER2 receptors |
Unknown |
Increased adipocyte lipolysis |
[58] |
Breast cancer |
In vitro |
Trastuzumab |
Inhibitor of HER2 receptors |
Increased lipogenesis |
Increased FAS promoter |
[59] |
Breast cancer |
In vitro |
Tamoxifen |
Inhibitor of oestrogen receptors (ERs) |
Increased lipogenesis |
Increased cholesterol pathway gene expression |
[60] |
Multiple cancer models |
In vitro and in vivo xenografts |
Anti-Angiogenic drugs |
Inhibitors of vascular endothelial growth factor (VEGF) |
Increased lipolysis |
Increased FFA uptake and FAO induced by hypoxia |
[61] |